Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease

Progress in Molecular Biology and Translational Science

Volumn 147, Issue , 2017, Pages 267-299

  Chen, Yunfei ^a   Peng, Wei ^a   Raffetto, Joseph D ^a   Khalil, Raouf A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cell signaling; Collagen; Extracellular matrix; Protein degradation; Proteinases; Remodeling

Indexed keywords

MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; TISSUE INHIBITOR OF METALLOPROTEINASE;

CHRONIC DISEASE; ENDOTHELIUM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HUMAN; HYDROSTATIC PRESSURE; HYPOXIA; INFLAMMATION; LOWER EXTREMITY VEIN; LOWER LIMB; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; SURGICAL APPROACH; VARICOSIS; VASCULAR SMOOTH MUSCLE; VEIN DISEASE; ANIMAL; DRUG EFFECTS; ENZYMOLOGY; METABOLISM; PATHOPHYSIOLOGY; VASCULAR REMODELING;

ANIMALS; CHRONIC DISEASE; HUMANS; LOWER EXTREMITY; MATRIX METALLOPROTEINASE INHIBITORS; MATRIX METALLOPROTEINASES; VARICOSE VEINS; VASCULAR REMODELING;

EID: 85015796531     PISSN: 18771173     EISSN: 18780814     Source Type: Book Series    
DOI: 10.1016/bs.pmbts.2017.02.003     Document Type: Chapter

References (132)

1. 1 Recek, C., Conception of the venous hemodynamics in the lower extremity. Angiology 57:5 (2006), 556–563.
2. 2 Lim, C.S., Davies, A.H., Pathogenesis of primary varicose veins. Br J Surg 96:11 (2009), 1231–1242.
3. 3 MacColl, E., Khalil, R.A., Matrix metalloproteinases as regulators of vein structure and function: implications in chronic venous disease. J Pharmacol Exp Ther 355:3 (2015), 410–428.
4. 4 Sansilvestri-Morel, P., Fioretti, F., Rupin, A., et al. Comparison of extracellular matrix in skin and saphenous veins from patients with varicose veins: does the skin reflect venous matrix changes?. Clin Sci (Lond) 112:4 (2007), 229–239.
5. 5 Eklof, B., Rutherford, R.B., Bergan, J.J., et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. J Vasc Surg 40:6 (2004), 1248–1252.
6. 6 Beebe-Dimmer, J.L., Pfeifer, J.R., Engle, J.S., Schottenfeld, D., The epidemiology of chronic venous insufficiency and varicose veins. Ann Epidemiol 15:3 (2005), 175–184.
7. 7 Zsoter, T., Cronin, R.F., Venous distensibility in patients with varicose veins. Can Med Assoc J 94:25 (1966), 1293–1297.
8. 8 Raffetto, J.D., Qiao, X., Beauregard, K.G., Khalil, R.A., Estrogen receptor-mediated enhancement of venous relaxation in female rat: implications in sex-related differences in varicose veins. J Vasc Surg 51:4 (2010), 972–981.
9. 9 Mekky, S., Schilling, R.S., Walford, J., Varicose veins in women cotton workers. An epidemiological study in England and Egypt. Br Med J 2:5657 (1969), 591–595.
10. 10 Jawien, A., The influence of environmental factors in chronic venous insufficiency. Angiology 54:suppl 1 (2003), S19–S31.
11. 11 Lacroix, P., Aboyans, V., Preux, P.M., Houles, M.B., Laskar, M., Epidemiology of venous insufficiency in an occupational population. Int Angiol 22:2 (2003), 172–176.
12. 12 Lee, S., Lee, W., Choe, Y., et al. Gene expression profiles in varicose veins using complementary DNA microarray. Dermatol Surg 31:4 (2005), 391–395.
13. 13 Ng, M.Y., Andrew, T., Spector, T.D., Jeffery, S., Linkage to the FOXC2 region of chromosome 16 for varicose veins in otherwise healthy, unselected sibling pairs. J Med Genet 42:3 (2005), 235–239.
14. 14 Serra, R., Buffone, G., de Franciscis, A., et al. A genetic study of chronic venous insufficiency. Ann Vasc Surg 26:5 (2012), 636–642.
15. 15 Delis, K.T., Gloviczki, P., Wennberg, P.W., Rooke, T.W., Driscoll, D.J., Hemodynamic impairment, venous segmental disease, and clinical severity scoring in limbs with Klippel–Trenaunay syndrome. J Vasc Surg 45:3 (2007), 561–567.
16. 16 Reagan, B., Folse, R., Lower limb venous dynamics in normal persons and children of patients with varicose veins. Surg Gynecol Obstet 132:1 (1971), 15–18.
17. 17 Saiki, S., Sakai, K., Saiki, M., et al. Varicose veins associated with CADASIL result from a novel mutation in the Notch3 gene. Neurology 67:2 (2006), 337–339.
18. 18 Badauy, C.M., Gomes, S.S., Sant'Ana Filho, M., Chies, J.A., Ehlers-Danlos syndrome (EDS) type IV: review of the literature. Clin Oral Investig 11:3 (2007), 183–187.
19. 19 Xu, H.M., Zhao, Y., Zhang, X.M., Zhu, T., Fu, W.G., Polymorphisms in MMP-9 and TIMP-2 in Chinese patients with varicose veins. J Surg Res 168:1 (2011), e143–e148.
20. 20 Anwar, M.A., Georgiadis, K.A., Shalhoub, J., Lim, C.S., Gohel, M.S., Davies, A.H., A review of familial, genetic, and congenital aspects of primary varicose vein disease. Circ Cardiovasc Genet 5:4 (2012), 460–466.
21. 21 Naoum, J.J., Hunter, G.C., Woodside, K.J., Chen, C., Current advances in the pathogenesis of varicose veins. J Surg Res 141:2 (2007), 311–316.
22. 22 Mannello, F., Medda, V., Ligi, D., Raffetto, J.D., Glycosaminoglycan sulodexide inhibition of MMP-9 gelatinase secretion and activity: possible pharmacological role against collagen degradation in vascular chronic diseases. Curr Vasc Pharmacol 11:3 (2013), 354–365.
23. 23 Naik, B., Kumar, M., Khanna, A.K., Suman, P.K., Clinico-histopathological study of varicose vein and role of matrix metalloproteinases-1, matrix metalloproteinases-9 and tissue inhibitor of matrix metalloproteinase-1 in varicose vein formation. Indian J Pathol Microbiol 59:1 (2016), 25–30.
24. 24 Gandhi, R.H., Irizarry, E., Nackman, G.B., Halpern, V.J., Mulcare, R.J., Tilson, M.D., Analysis of the connective tissue matrix and proteolytic activity of primary varicose veins. J Vasc Surg 18:5 (1993), 814–820.
25. 25 Haviarova, Z., Weismann, P., Stvrtinova, V., Benuska, J., The determination of the collagen and elastin amount in the human varicose vein by the computer morphometric method. Gen Physiol Biophys 18:suppl 1 (1999), 30–33.
26. 26 Kockx, M.M., Knaapen, M.W., Bortier, H.E., Cromheeke, K.M., Boutherin-Falson, O., Finet, M., Vascular remodeling in varicose veins. Angiology 49:11 (1998), 871–877.
27. 27 Venturi, M., Bonavina, L., Annoni, F., et al. Biochemical assay of collagen and elastin in the normal and varicose vein wall. J Surg Res 60:1 (1996), 245–248.
28. 28 Corcos, L., De Anna, D., Dini, M., Macchi, C., Ferrari, P.A., Dini, S., Proximal long saphenous vein valves in primary venous insufficiency. J Mal Vasc 25:1 (2000), 27–36.
29. 29 Psaila, J.V., Melhuish, J., Viscoelastic properties and collagen content of the long saphenous vein in normal and varicose veins. Br J Surg 76:1 (1989), 37–40.
30. 30 Ono, T., Bergan, J.J., Schmid-Schonbein, G.W., Takase, S., Monocyte infiltration into venous valves. J Vasc Surg 27:1 (1998), 158–166.
31. 31 Raffetto, J.D., Khalil, R.A., Mechanisms of varicose vein formation: valve dysfunction and wall dilation. Phlebology 23:2 (2008), 85–98.
32. 32 Dzieciuchowicz, L., Espinosa, G., Paramo, J.A., Increased levels of metalloproteinase 10 and hemostatic markers in patients with noncomplicated primary varicose veins. Clin Appl Thromb Hemost 21:7 (2015), 684–687.
33. 33 Gillespie, D.L., Patel, A., Fileta, B., et al. Varicose veins possess greater quantities of MMP-1 than normal veins and demonstrate regional variation in MMP-1 and MMP-13. J Surg Res 106:2 (2002), 233–238.
34. 34 Woodside, K.J., Hu, M., Burke, A., et al. Morphologic characteristics of varicose veins: possible role of metalloproteinases. J Vasc Surg 38:1 (2003), 162–169.
35. 35 Gomez, I., Benyahia, C., Louedec, L., et al. Decreased PGE(2) content reduces MMP-1 activity and consequently increases collagen density in human varicose vein. PLoS One, 9(2), 2014, e88021.
36. 36 Serra, R., Gallelli, L., Butrico, L., et al. From varices to venous ulceration: the story of chronic venous disease described by metalloproteinases. Int Wound J 14:1 (2017), 233–240.
37. 37 Amato, B., Coretti, G., Compagna, R., et al. Role of matrix metalloproteinases in non-healing venous ulcers. Int Wound J 12:6 (2015), 641–645.
38. 38 Serra, R., Grande, R., Buffone, G., et al. Extracellular matrix assessment of infected chronic venous leg ulcers: role of metalloproteinases and inflammatory cytokines. Int Wound J 13:1 (2016), 53–58.
39. 39 Asanuma, K., Magid, R., Johnson, C., Nerem, R.M., Galis, Z.S., Uniaxial strain upregulates matrix-degrading enzymes produced by human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 284:5 (2003), H1778–H1784.
40. 40 Raffetto, J.D., Qiao, X., Koledova, V.V., Khalil, R.A., Prolonged increases in vein wall tension increase matrix metalloproteinases and decrease constriction in rat vena cava: potential implications in varicose veins. J Vasc Surg 48:2 (2008), 447–456.
41. 41 Lim, C.S., Qiao, X., Reslan, O.M., et al. Prolonged mechanical stretch is associated with upregulation of hypoxia-inducible factors and reduced contraction in rat inferior vena cava. J Vasc Surg 53:3 (2011), 764–773.
42. 42 Schmid-Schonbein, G.W., Takase, S., Bergan, J.J., New advances in the understanding of the pathophysiology of chronic venous insufficiency. Angiology 52:suppl 1 (2001), S27–S34.
43. 43 Takase, S., Pascarella, L., Bergan, J.J., Schmid-Schonbein, G.W., Hypertension-induced venous valve remodeling. J Vasc Surg 39:6 (2004), 1329–1334.
44. 44 Saito, S., Trovato, M.J., You, R., et al. Role of matrix metalloproteinases 1, 2, and 9 and tissue inhibitor of matrix metalloproteinase-1 in chronic venous insufficiency. J Vasc Surg 34:5 (2001), 930–938.
45. 45 Kucukguven, A., Khalil, R.A., Matrix metalloproteinases as potential targets in the venous dilation associated with varicose veins. Curr Drug Targets 14:3 (2013), 287–324.
46. 46 Sayer, G.L., Smith, P.D., Immunocytochemical characterisation of the inflammatory cell infiltrate of varicose veins. Eur J Vasc Endovasc Surg 28:5 (2004), 479–483.
47. 47 Aunapuu, M., Arend, A., Histopathological changes and expression of adhesion molecules and laminin in varicose veins. Vasa 34:3 (2005), 170–175.
48. 48 Jacob, M.P., Cazaubon, M., Scemama, A., et al. Plasma matrix metalloproteinase-9 as a marker of blood stasis in varicose veins. Circulation 106:5 (2002), 535–538.
49. 49 Sato, H., Kita, M., Seiki, M., v-Src activates the expression of 92-kDa type IV collagenase gene through the AP-1 site and the GT box homologous to retinoblastoma control elements. A mechanism regulating gene expression independent of that by inflammatory cytokines. J Biol Chem 268:31 (1993), 23460–23468.
50. 50 Reddy, V.S., Prabhu, S.D., Mummidi, S., et al. Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signaling and MMP-9 in part via EMMPRIN and through AP-1 and NF-kappaB activation. Am J Physiol Heart Circ Physiol 299:4 (2010), H1242–H1254.
51. 51 Arbiser, J.L., Petros, J., Klafter, R., et al. Reactive oxygen generated by Nox1 triggers the angiogenic switch. Proc Natl Acad Sci U S A 99:2 (2002), 715–720.
52. 52 Zubkova, E.S., Men'shikov, M.Y., Plekhanova, O.S., Beloglazova, I.B., Ratner, E.I., Parfenova, E.V., Urokinase stimulates production of matrix metalloproteinase-9 in fibroblasts with involvement of reactive oxygen species. Bull Exp Biol Med 157:1 (2014), 18–21.
53. 53 Fu, X., Kao, J.L., Bergt, C., et al. Oxidative cross-linking of tryptophan to glycine restrains matrix metalloproteinase activity: specific structural motifs control protein oxidation. J Biol Chem 279:8 (2004), 6209–6212.
54. 54 Milkiewicz, M., Doyle, J.L., Fudalewski, T., Ispanovic, E., Aghasi, M., Haas, T.L., HIF-1alpha and HIF-2alpha play a central role in stretch-induced but not shear-stress-induced angiogenesis in rat skeletal muscle. J Physiol 583:pt 2 (2007), 753–766.
55. 55 Kim, C.H., Cho, Y.S., Chun, Y.S., Park, J.W., Kim, M.S., Early expression of myocardial HIF-1alpha in response to mechanical stresses: regulation by stretch-activated channels and the phosphatidylinositol 3-kinase signaling pathway. Circ Res 90:2 (2002), E25–E33.
56. 56 Thodeti, C.K., Matthews, B., Ravi, A., et al. TRPV4 channels mediate cyclic strain-induced endothelial cell reorientation through integrin-to-integrin signaling. Circ Res 104:9 (2009), 1123–1130.
57. 57 Lim, C.S., Kiriakidis, S., Paleolog, E.M., Davies, A.H., Increased activation of the hypoxia-inducible factor pathway in varicose veins. J Vasc Surg 55:5 (2012), 1427–1439.
58. 58 Misra, S., Fu, A.A., Rajan, D.K., et al. Expression of hypoxia inducible factor-1 alpha, macrophage migration inhibition factor, matrix metalloproteinase-2 and -9, and their inhibitors in hemodialysis grafts and arteriovenous fistulas. J Vasc Interv Radiol 19:2 pt 1 (2008), 252–259.
59. 59 Foda, H.D., Rollo, E.E., Drews, M., et al. Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340). Am J Respir Cell Mol Biol 25:6 (2001), 717–724.
60. 60 Norgauer, J., Hildenbrand, T., Idzko, M., et al. Elevated expression of extracellular matrix metalloproteinase inducer (CD147) and membrane-type matrix metalloproteinases in venous leg ulcers. Br J Dermatol 147:6 (2002), 1180–1186.
61. 61 Majed, B.H., Khalil, R.A., Molecular mechanisms regulating the vascular prostacyclin pathways and their adaptation during pregnancy and in the newborn. Pharmacol Rev 64:3 (2012), 540–582.
62. 62 Lee, J., Banu, S.K., Subbarao, T., Starzinski-Powitz, A., Arosh, J.A., Selective inhibition of prostaglandin E2 receptors EP2 and EP4 inhibits invasion of human immortalized endometriotic epithelial and stromal cells through suppression of metalloproteinases. Mol Cell Endocrinol 332:1–2 (2011), 306–313.
63. 63 Takai, S., Jin, D., Chen, H., et al. Chymase inhibition improves vascular dysfunction and survival in stroke-prone spontaneously hypertensive rats. J Hypertens 32:8 (2014), 1637–1649.
64. 64 Yin, Z., Sada, A.A., Reslan, O.M., Narula, N., Khalil, R.A., Increased MMPs expression and decreased contraction in the rat myometrium during pregnancy and in response to prolonged stretch and sex hormones. Am J Physiol Endocrinol Metab 303:1 (2012), E55–E70.
65. 65 Dang, Y., Li, W., Tran, V., Khalil, R.A., EMMPRIN-mediated induction of uterine and vascular matrix metalloproteinases during pregnancy and in response to estrogen and progesterone. Biochem Pharmacol 86:6 (2013), 734–747.
66. 66 Serra, R., Gallelli, L., Conti, A., et al. The effects of sulodexide on both clinical and molecular parameters in patients with mixed arterial and venous ulcers of lower limbs. Drug Des Devel Ther 8 (2014), 519–527.
67. 67 Badier-Commander, C., Verbeuren, T., Lebard, C., Michel, J.B., Jacob, M.P., Increased TIMP/MMP ratio in varicose veins: a possible explanation for extracellular matrix accumulation. J Pathol 192:1 (2000), 105–112.
68. 68 Kirsch, D., Dienes, H.P., Kuchle, R., et al. Changes in the extracellular matrix of the vein wall—the cause of primary varicosis?. Vasa 29:3 (2000), 173–177.
69. 69 Sansilvestri-Morel, P., Rupin, A., Badier-Commander, C., et al. Imbalance in the synthesis of collagen type I and collagen type III in smooth muscle cells derived from human varicose veins. J Vasc Res 38:6 (2001), 560–568.
70. 70 Sansilvestri-Morel, P., Rupin, A., Jullien, N.D., et al. Decreased production of collagen Type III in cultured smooth muscle cells from varicose vein patients is due to a degradation by MMPs: possible implication of MMP-3. J Vasc Res 42:5 (2005), 388–398.
71. 71 Xiao, Y., Huang, Z., Yin, H., Lin, Y., Wang, S., In vitro differences between smooth muscle cells derived from varicose veins and normal veins. J Vasc Surg 50:5 (2009), 1149–1154.
72. 72 Shi, Z.D., Ji, X.Y., Berardi, D.E., Qazi, H., Tarbell, J.M., Interstitial flow induces MMP-1 expression and vascular SMC migration in collagen I gels via an ERK1/2-dependent and c-Jun-mediated mechanism. Am J Physiol Heart Circ Physiol 298:1 (2010), H127–H135.
73. 73 Jin, U.H., Suh, S.J., Chang, H.W., et al. Tanshinone IIA from Salvia miltiorrhiza BUNGE inhibits human aortic smooth muscle cell migration and MMP-9 activity through AKT signaling pathway. J Cell Biochem 104:1 (2008), 15–26.
74. 74 Morla, A.O., Mogford, J.E., Control of smooth muscle cell proliferation and phenotype by integrin signaling through focal adhesion kinase. Biochem Biophys Res Commun 272:1 (2000), 298–302.
75. 75 Karsdal, M.A., Larsen, L., Engsig, M.T., et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem 277:46 (2002), 44061–44067.
76. 76 Mao, D., Zhang, Y., Lu, H., Zhang, H., Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment. Tumour Biol 35:8 (2014), 8217–8223.
77. 77 Zhang, H., Chalothorn, D., Jackson, L.F., Lee, D.C., Faber, J.E., Transactivation of epidermal growth factor receptor mediates catecholamine-induced growth of vascular smooth muscle. Circ Res 95:10 (2004), 989–997.
78. 78 Hollborn, M., Stathopoulos, C., Steffen, A., Wiedemann, P., Kohen, L., Bringmann, A., Positive feedback regulation between MMP-9 and VEGF in human RPE cells. Invest Ophthalmol Vis Sci 48:9 (2007), 4360–4367.
79. 79 Cui, Y., Sun, Y.W., Lin, H.S., et al. Platelet-derived growth factor-BB induces matrix metalloproteinase-2 expression and rat vascular smooth muscle cell migration via ROCK and ERK/p38 MAPK pathways. Mol Cell Biochem 393:1–2 (2014), 255–263.
80. 80 Rao, V.H., Kansal, V., Stoupa, S., Agrawal, D.K., MMP-1 and MMP-9 regulate epidermal growth factor-dependent collagen loss in human carotid plaque smooth muscle cells. Physiol Rep, 2(2), 2014, e00224.
81. 81 Chew, D.K., Conte, M.S., Khalil, R.A., Matrix metalloproteinase-specific inhibition of Ca2 + entry mechanisms of vascular contraction. J Vasc Surg 40:5 (2004), 1001–1010.
82. 82 Raffetto, J.D., Barros, Y.V., Wells, A.K., Khalil, R.A., MMP-2 induced vein relaxation via inhibition of [Ca2 +]e-dependent mechanisms of venous smooth muscle contraction. Role of RGD peptides. J Surg Res 159:2 (2010), 755–764.
83. 83 Waitkus-Edwards, K.R., Martinez-Lemus, L.A., Wu, X., et al. alpha(4)beta(1) Integrin activation of L-type calcium channels in vascular smooth muscle causes arteriole vasoconstriction. Circ Res 90:4 (2002), 473–480.
84. 84 Raffetto, J.D., Ross, R.L., Khalil, R.A., Matrix metalloproteinase 2-induced venous dilation via hyperpolarization and activation of K + channels: relevance to varicose vein formation. J Vasc Surg 45:2 (2007), 373–380.
85. 85 Feletou, M., Vanhoutte, P.M., Endothelium-derived hyperpolarizing factor: where are we now?. Arterioscler Thromb Vasc Biol 26:6 (2006), 1215–1225.
86. 86 Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifi, S., Kuliopulos, A., PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120:3 (2005), 303–313.
87. 87 McNamara, C.A., Sarembock, I.J., Gimple, L.W., Fenton, J.W. 2nd, Coughlin, S.R., Owens, G.K., Thrombin stimulates proliferation of cultured rat aortic smooth muscle cells by a proteolytically activated receptor. J Clin Invest 91:1 (1993), 94–98.
88. 88 Coughlin, S.R., Thrombin signalling and protease-activated receptors. Nature 407:6801 (2000), 258–264.
89. 89 Garcia, J.G., Patterson, C., Bahler, C., Aschner, J., Hart, C.M., English, D., Thrombin receptor activating peptides induce Ca2 + mobilization, barrier dysfunction, prostaglandin synthesis, and platelet-derived growth factor mRNA expression in cultured endothelium. J Cell Physiol 156:3 (1993), 541–549.
90. 90 Lee, H.Y., You, H.J., Won, J.Y., et al. Forkhead factor, FOXO3a, induces apoptosis of endothelial cells through activation of matrix metalloproteinases. Arterioscler Thromb Vasc Biol 28:2 (2008), 302–308.
91. 91 Lattimer, C.R., Kalodiki, E., Kafeza, M., Azzam, M., Geroulakos, G., Quantifying the degree graduated elastic compression stockings enhance venous emptying. Eur J Vasc Endovasc Surg 47:1 (2014), 75–80.
92. 92 Lattimer, C.R., Azzam, M., Kalodiki, E., Makris, G.C., Geroulakos, G., Compression stockings significantly improve hemodynamic performance in post-thrombotic syndrome irrespective of class or length. J Vasc Surg 58:1 (2013), 158–165.
93. 93 Raffetto, J.D., Khalil, R.A., Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol 75:2 (2008), 346–359.
94. 94 Le Devehat, C., Khodabandehlou, T., Vimeux, M., Kempf, C., Evaluation of haemorheological and microcirculatory disturbances in chronic venous insufficiency: activity of Daflon 500 mg. Int J Microcirc Clin Exp 17:suppl 1 (1997), 27–33.
95. 95 Cesarone, M.R., Belcaro, G., Pellegrini, L., et al. Venoruton vs Daflon: evaluation of effects on quality of life in chronic venous insufficiency. Angiology 57:2 (2006), 131–138.
96. 96 Raffetto, J.D., Khalil, R.A., Ca(2 +)-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins. J Vasc Surg 54:2 (2011), 489–496.
97. 97 Raffetto, J.D., Eberhardt, R.T., Dean, S.M., Ligi, D., Mannello, F., Pharmacologic treatment to improve venous leg ulcer healing. J Vasc Surg Venous Lymphat Disord 4:3 (2016), 371–374.
98. 98 Mann, M.W., Sclerotherapy: it is back and better. Clin Plast Surg 38:3 (2011), 475–487 vii.
99. 99 King, J.T., O'Byrne, M., Vasquez, M., Wright, D., Treatment of truncal incompetence and varicose veins with a single administration of a new polidocanol endovenous microfoam preparation improves symptoms and appearance. Eur J Vasc Endovasc Surg 50:6 (2015), 784–793.
100. 100 Proebstle, T.M., Lehr, H.A., Kargl, A., et al. Endovenous treatment of the greater saphenous vein with a 940-nm diode laser: thrombotic occlusion after endoluminal thermal damage by laser-generated steam bubbles. J Vasc Surg 35:4 (2002), 729–736.
101. 101 Merchant, R.F., Pichot, O., Myers, K.A., Four-year follow-up on endovascular radiofrequency obliteration of great saphenous reflux. Dermatol Surg 31:2 (2005), 129–134.
102. 102 Min, R.J., Khilnani, N., Zimmet, S.E., Endovenous laser treatment of saphenous vein reflux: long-term results. J Vasc Interv Radiol 14:8 (2003), 991–996.
103. 103 Aremu, M.A., Mahendran, B., Butcher, W., et al. Prospective randomized controlled trial: conventional versus powered phlebectomy. J Vasc Surg 39:1 (2004), 88–94.
104. 104 Bootun, R., Lane, T.R., Davies, A.H., The advent of non-thermal, non-tumescent techniques for treatment of varicose veins. Phlebology 31:1 (2016), 5–14.
105. 105 Tekin, A.I., Tuncer, O.N., Memetoglu, M.E., et al. Nonthermal, nontumescent endovenous treatment of varicose veins. Ann Vasc Surg 36 (2016), 231–235.
106. 106 Bode, W., Fernandez-Catalan, C., Grams, F., et al. Insights into MMP–TIMP interactions. Ann N Y Acad Sci 878 (1999), 73–91.
107. 107 Nagase, H., Visse, R., Murphy, G., Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69:3 (2006), 562–573.
108. 108 Baker, A.H., Edwards, D.R., Murphy, G., Metalloproteinase inhibitors: biological actions and therapeutic opportunities. J Cell Sci 115:pt 19 (2002), 3719–3727.
109. 109 Batra, J., Robinson, J., Soares, A.S., Fields, A.P., Radisky, D.C., Radisky, E.S., Matrix metalloproteinase-10 (MMP-10) interaction with tissue inhibitors of metalloproteinases TIMP-1 and TIMP-2: binding studies and crystal structure. J Biol Chem 287:19 (2012), 15935–15946.
110. 110 Meng, Q., Malinovskii, V., Huang, W., et al. Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1′ residue of substrate. J Biol Chem 274:15 (1999), 10184–10189.
111. 111 Aravind, B., Saunders, B., Navin, T., et al. Inhibitory effect of TIMP influences the morphology of varicose veins. Eur J Vasc Endovasc Surg 40:6 (2010), 754–765.
112. 112 Badier-Commander, C., Couvelard, A., Henin, D., Verbeuren, T., Michel, J.B., Jacob, M.P., Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study. J Pathol 193:3 (2001), 398–407.
113. 113 Caimi, G., Ferrara, F., Montana, M., et al. Behaviour of the plasma concentration of gelatinases and their tissue inhibitors in subjects with venous leg ulcers. Clin Hemorheol Microcirc 60:3 (2015), 309–316.
114. 114 Li, P.C., Pan, C.H., Sheu, M.J., Wu, C.C., Ma, W.F., Wu, C.H., Deep sea water prevents balloon angioplasty-induced hyperplasia through MMP-2: an in vitro and in vivo study. PLoS One, 9(5), 2014, e96927.
115. 115 Benjamin, M.M., Khalil, R.A., Matrix metalloproteinase inhibitors as investigative tools in the pathogenesis and management of vascular disease. EXS 103 (2012), 209–279.
116. 116 Hu, J., Van den Steen, P.E., Sang, Q.X., Opdenakker, G., Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat Rev Drug Discov 6:6 (2007), 480–498.
117. 117 Jacobsen, J.A., Major Jourden, J.L., Miller, M.T., Cohen, S.M., To bind zinc or not to bind zinc: an examination of innovative approaches to improved metalloproteinase inhibition. Biochim Biophys Acta 1803:1 (2010), 72–94.
118. 118 Scozzafava, A., Supuran, C.T., Carbonic anhydrase and matrix metalloproteinase inhibitors: sulfonylated amino acid hydroxamates with MMP inhibitory properties act as efficient inhibitors of CA isozymes I, II, and IV, and N-hydroxysulfonamides inhibit both these zinc enzymes. J Med Chem 43:20 (2000), 3677–3687.
119. 119 Pochetti, G., Gavuzzo, E., Campestre, C., et al. Structural insight into the stereoselective inhibition of MMP-8 by enantiomeric sulfonamide phosphonates. J Med Chem 49:3 (2006), 923–931.
120. 120 Wojtowicz-Praga, S.M., Dickson, R.B., Hawkins, M.J., Matrix metalloproteinase inhibitors. Invest New Drugs 15:1 (1997), 61–75.
121. 121 Skiles, J.W., Gonnella, N.C., Jeng, A.Y., The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Curr Med Chem 8:4 (2001), 425–474.
122. 122 Puerta, D.T., Lewis, J.A., Cohen, S.M., New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups. J Am Chem Soc 126:27 (2004), 8388–8389.
123. 123 Bernardo, M.M., Brown, S., Li, Z.H., Fridman, R., Mobashery, S., Design, synthesis, and characterization of potent, slow-binding inhibitors that are selective for gelatinases. J Biol Chem 277:13 (2002), 11201–11207.
124. 124 Johnson, A.R., Pavlovsky, A.G., Ortwine, D.F., et al. Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects. J Biol Chem 282:38 (2007), 27781–27791.
125. 125 Chetty, C., Bhoopathi, P., Joseph, P., Chittivelu, S., Rao, J.S., Lakka, S., Adenovirus-mediated small interfering RNA against matrix metalloproteinase-2 suppresses tumor growth and lung metastasis in mice. Mol Cancer Ther 5:9 (2006), 2289–2299.
126. 126 Dorecka, M., Francuz, T., Garczorz, W., Siemianowicz, K., Romaniuk, W., The influence of elastin degradation products, glucose and atorvastatin on metalloproteinase-1, -2, -9 and tissue inhibitor of metalloproteinases-1, -2, -3 expression in human retinal pigment epithelial cells. Acta Biochim Pol 61:2 (2014), 265–270.
127. 127 Luan, Z., Chase, A.J., Newby, A.C., Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscler Thromb Vasc Biol 23:5 (2003), 769–775.
128. 128 Ichihara, S., Noda, A., Nagata, K., et al. Pravastatin increases survival and suppresses an increase in myocardial matrix metalloproteinase activity in a rat model of heart failure. Cardiovasc Res 69:3 (2006), 726–735.
129. 129 Chen, Q., Jin, M., Yang, F., Zhu, J., Xiao, Q., Zhang, L., Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm, 2013, 2013, 928315.
130. 130 Serra, R., Gallelli, L., Buffone, G., et al. Doxycycline speeds up healing of chronic venous ulcers. Int Wound J 12:2 (2015), 179–184.
131. 131 Renkiewicz, R., Qiu, L., Lesch, C., et al. Broad-spectrum matrix metalloproteinase inhibitor marimastat-induced musculoskeletal side effects in rats. Arthritis Rheum 48:6 (2003), 1742–1749.
132. 132 Li, J., Rush, T.S. 3rd, Li, W., et al. Synthesis and SAR of highly selective MMP-13 inhibitors. Bioorg Med Chem Lett 15:22 (2005), 4961–4966.